BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26116622)

  • 1. FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs.
    Kim KH; Lee MS
    J Endocrinol; 2015 Jul; 226(1):R1-16. PubMed ID: 26116622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives.
    Woo YC; Xu A; Wang Y; Lam KS
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):489-96. PubMed ID: 23134073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the Physiology of FGF21.
    Fisher FM; Maratos-Flier E
    Annu Rev Physiol; 2016; 78():223-41. PubMed ID: 26654352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGF21-based pharmacotherapy--potential utility for metabolic disorders.
    Gimeno RE; Moller DE
    Trends Endocrinol Metab; 2014 Jun; 25(6):303-11. PubMed ID: 24709036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rush to the fire: FGF21 extinguishes metabolic stress, metaflammation and tissue damage.
    Luo Y; Ye S; Chen X; Gong F; Lu W; Li X
    Cytokine Growth Factor Rev; 2017 Dec; 38():59-65. PubMed ID: 28887067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGF21 as a Stress Hormone: The Roles of FGF21 in Stress Adaptation and the Treatment of Metabolic Diseases.
    Kim KH; Lee MS
    Diabetes Metab J; 2014 Aug; 38(4):245-51. PubMed ID: 25215270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice.
    Kim HW; Lee JE; Cha JJ; Hyun YY; Kim JE; Lee MH; Song HK; Nam DH; Han JY; Han SY; Han KH; Kang YS; Cha DR
    Endocrinology; 2013 Sep; 154(9):3366-76. PubMed ID: 23825123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of longevity by FGF21: Interaction between energy metabolism and stress responses.
    Salminen A; Kaarniranta K; Kauppinen A
    Ageing Res Rev; 2017 Aug; 37():79-93. PubMed ID: 28552719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor 21: effects on carbohydrate and lipid metabolism in health and disease.
    Kralisch S; Fasshauer M
    Curr Opin Clin Nutr Metab Care; 2011 Jul; 14(4):354-9. PubMed ID: 21505329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF21: a novel prospect for the treatment of metabolic diseases.
    Kharitonenkov A; Shanafelt AB
    Curr Opin Investig Drugs; 2009 Apr; 10(4):359-64. PubMed ID: 19337957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus.
    So WY; Leung PS
    Med Res Rev; 2016 Jul; 36(4):672-704. PubMed ID: 27031294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic actions of fibroblast growth factor 21.
    Cuevas-Ramos D; Aguilar-Salinas CA; Gómez-Pérez FJ
    Curr Opin Pediatr; 2012 Aug; 24(4):523-9. PubMed ID: 22732636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases.
    Zhang F; Yu L; Lin X; Cheng P; He L; Li X; Lu X; Tan Y; Yang H; Cai L; Zhang C
    Mol Endocrinol; 2015 Oct; 29(10):1400-13. PubMed ID: 26308386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-34a and Impaired FGF19/21 Signaling in Obesity.
    Fu T; Kemper JK
    Vitam Horm; 2016; 101():175-96. PubMed ID: 27125742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Nuanced Metabolic Functions of Endogenous FGF21 Depend on the Nature of the Stimulus, Tissue Source, and Experimental Model.
    Spann RA; Morrison CD; den Hartigh LJ
    Front Endocrinol (Lausanne); 2021; 12():802541. PubMed ID: 35046901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic.
    Geng L; Lam KSL; Xu A
    Nat Rev Endocrinol; 2020 Nov; 16(11):654-667. PubMed ID: 32764725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus.
    Dostálová I; Haluzíková D; Haluzík M
    Physiol Res; 2009; 58(1):1-7. PubMed ID: 19331512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases.
    Cheng P; Zhang F; Yu L; Lin X; He L; Li X; Lu X; Yan X; Tan Y; Zhang C
    J Diabetes Res; 2016; 2016():1540267. PubMed ID: 27247947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor 21: a promising therapeutic target in obesity-related diseases.
    Cheung BM; Deng HB
    Expert Rev Cardiovasc Ther; 2014 Jun; 12(6):659-66. PubMed ID: 24697521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice.
    Lin Z; Tian H; Lam KS; Lin S; Hoo RC; Konishi M; Itoh N; Wang Y; Bornstein SR; Xu A; Li X
    Cell Metab; 2013 May; 17(5):779-89. PubMed ID: 23663741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.